Daily Roundup

EMV.ASX NEU.ASX DHG.ASX FBR.ASX FND.ASX

EMVision Commences Pivotal Trial for Emu Brain Scanner

EMVision Medical Devices has kicked off the pivotal validation trial for its Emu point-of-care brain scanner. The first sites in Australia and the US have been activated, with more to follow. This critical trial aims to demonstrate the device's ability to detect intracranial haemorrhage with over 80% sensitivity and specificity, a key step in obtaining regulatory approval and commercialising the Emu.

The 300-patient trial will run across 4 sites in the US and 2 in Australia, led by the experienced clinical research organisation Vastrax. In parallel, EMVision will conduct a 'Continuous Innovation Study' to further enhance the Emu's features and expand its diagnostic AI capabilities. Successful completion of the pivotal trial is expected to support EMVision's FDA De Novo clearance application and serve as the predicate device for its upcoming First Responder product.

Neuren Targets Hypoxic-Ischemic Encephalopathy with NNZ-2591

Neuren Pharmaceuticals is expanding the development of its lead candidate NNZ-2591 to treat hypoxic-ischemic encephalopathy (HIE), a devastating brain injury in newborns. HIE is a leading cause of neonatal death and disability, and the current standard of care, hypothermia, only provides modest improvements.

Neuren believes NNZ-2591 can offer a highly differentiated treatment, addressing both the acute effects and chronic impairments of HIE. The company plans to seek Orphan Drug and Rare Pediatric Disease designations from the FDA as it targets a pre-IND meeting in Q4 2025 before initiating clinical trials. Neuren is excited to work with experts in the field to potentially transform the treatment landscape for children and families affected by this debilitating condition.

Domain Receives Improved Proposal from CoStar

Domain Holdings Australia has received an improved, non-binding indicative proposal from CoStar Group to acquire the company for $4.43 per share in cash. This represents a 42% premium to Domain's previous closing price and a 5.5% uplift on CoStar's earlier $4.20 per share offer.

The Domain Board has unanimously determined to engage with CoStar and facilitate due diligence. Subject to finalising an implementation agreement and an independent expert's conclusion that the deal is in the best interests of shareholders, Domain's directors intend to unanimously recommend the transaction. Eligible shareholders may also receive up to an additional $0.04 per share in value through franking credits.

FBR Completes $6.3M Placement, Outlines Cost-Cutting Measures

FBR Ltd has successfully completed a $6.3 million capital raising, issuing new shares at $0.01 each. The funds will provide additional working capital and support the company's restructuring efforts.

FBR is implementing a cost rationalisation program to reduce its annual costs by around 70%. This will involve significant headcount reductions, facility consolidation, salary cuts for directors and founders, and a 25% decrease in non-executive directors. Despite these measures, FBR will retain a core technical team to continue its Hadrian X market entry strategy and other near-term initiatives, including discussions with industry players in steel, mining, energy and construction.

Findi Offers Shareholders Discounted Share Purchase Plan

Findi Ltd is providing eligible shareholders the opportunity to participate in a Share Purchase Plan, allowing them to purchase up to $30,000 worth of shares at a discounted price of $4.00 per share. This represents a 12.3% discount to Findi's last closing price.

The company is seeking to raise $5 million through the offer, with the potential to increase or scale back the size of the SPP if demand exceeds this target. The SPP is open to all shareholders on Findi's register as of March 19, 2025, with no brokerage or transaction costs for participating investors. The offer closes on April 11, 2025.